ArticleBMC pharmacology & toxicology2026
Development and application of a simple LC-MS/MS method for therapeutic drug monitoring to guide colistin dosing in critically Ill patients.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study aims to develop a simple, rapid, and cost-effective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determining the concentration of colistin in human serum, including its two active components, colistin A and colistin B, to support routine therapeutic drug monitoring (TDM).
methodsProtein precipitation was performed using pure acetonitrile, with polymyxin B1 as the internal standard (IS). Chromatographic separation was achieved using a Phenomenex KINETEX XB-C18 column (2.6 μm, 3 × 50 mm) with a gradient elution system consisting of 0.1% formic acid (FA) in water and pure acetonitrile as the mobile phase. Detection was carried out using an electrospray ionization (ESI) source in positive ion mode with multiple reaction monitoring (MRM). After applying the validated method to critically ill patients for approximately one year, we used the receiver operating characteristic (ROC) curve to identify the preliminary cut-off value of colistin trough concentration for predicting acute kidney injury (AKI).
resultsThe total runtime for chromatographic separation and mass spectrometric detection was 5 min. Excellent linearity was achieved over the concentration range of 0.27-8.69 µg/mL for colistin A and 0.08-2.56 µg/mL for colistin B, with R
conclusionThe validated method enables simultaneous and precise quantification of the two active substances, with a simple procedure and minimal analytical cost. The utility of TDM in critically ill patients is paramount for individualizing dosing regimens to optimize outcomes and safety. Specifically, the correlation between trough concentration and AKI risk highlights the importance for clinicians to monitor renal function during colistin treatment to prevent drug-induced AKI. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.